Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.3650 (3.25%) ($9.3650 - $9.3950) on Mon. Jan. 31, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.39% (three month average) | RSI | 51 | Latest Price | $9.3650(3.25%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.5% a day on average for past five trading days. | Weekly Trend | FOLD declines -3.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(64%) IWO(54%) IWM(51%) IWC(50%) XBI(49%) | Factors Impacting FOLD price | FOLD will decline at least -2.195% in a week (0% probabilities). VIXM(-30%) VXX(-13%) UUP(-12%) UNG(-9%) EDOC(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.195% (StdDev 4.39%) | Hourly BBV | 1.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-13.18(-240.74%) | Resistance Level | $10.05 | 5 Day Moving Average | $9.16(2.24%) | 10 Day Moving Average | $9.25(1.24%) | 20 Day Moving Average | $10.05(-6.82%) | To recent high | -24.8% | To recent low | 8% | Market Cap | $2.418b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |